Cambrex sells drug product business; Landmark to work with Galapagos; Genezen locks $18.5M equity boost 

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more. 

CD­MO Cam­brex sold its drug prod­uct busi­ness unit to API sup­pli­er No­ram­co, ac­cord­ing to a Nov. 2 press re­lease. As a part of the pur­chase, No­ram­co will re­vert back to its Ha­lo Phar­ma­ceu­ti­cal brand name. The busi­ness unit, with fa­cil­i­ties in Québec, Cana­da, and Whip­pa­ny, NJ, of­fers clin­i­cal and com­mer­cial man­u­fac­tur­ing and pack­ag­ing ser­vices, among oth­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.